Cibus (CBUS) Stock
Small plant breeding company developing improved crop traits. Here's the price, business snapshot, and what's worth knowing about Cibus in October 2026.
Cibus Inc (CBUS) is a small‑capitalisation company operating in agricultural biotechnology, focusing on precision plant breeding and trait development. With a market capitalisation of about $84 million, it is a development‑stage business where commercial progress depends on successful research, regulatory outcomes and partner or customer adoption. Investors should know that revenue at this stage can be limited and the company may rely on partnerships, grants or capital markets for funding. Shares can be thinly traded and subject to significant price swings. Key areas to review include the company’s pipeline, any licensing or collaboration agreements, published trial results and cash runway. Given the specialised science, long development timelines and regulatory uncertainty, Cibus tends to suit investors who understand biotech/agritech risks, can tolerate volatility and have a longer investment horizon. This is general information for education, not personalised financial advice.
About This Stock
CIBUS INC
CBUS
Current Price
$1.39
Potential 12 Month Profit
635.63%
Sector
N/A
Industry
N/A
Ticker
CBUS
Market Cap
$106.62M
Potential 12 Month Profit
635.63%
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cibus Inc. stock with a target price of $10.67, indicating good growth potential.
Financial Health
Cibus Inc is generating modest revenue and cash flow, but its financial position could improve.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage growth
Small‑cap profile means potential upside if development milestones are met, though outcomes and timelines are uncertain and share prices can be volatile.
Technology focus
Precision breeding and trait development are central to the business; technical promise must still clear regulatory and market adoption hurdles.
Partnerships matter
Commercial scale often relies on collaborations and licences with larger agribusinesses; progress can be steady but uneven and may require additional funding.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.